Bristol-Myers, Roche team up on melanoma drugs

Print
Email
|

Associated Press

Posted on June 2, 2011 at 8:01 AM

Updated Thursday, Jun 2 at 8:01 AM

NEW YORK (AP) — Drugmakers Bristol-Myers Squibb Co. and Roche AG said Thursday they will team up to study a potential combination treatment for melanoma.

The companies said they will conduct a clinical trial of a regimen that combines Bristol-Myers' drug Yervoy, which was approved in March, and Roche's drug candidate vemurafenib. The study will be designed to test the safety of the drug combination and its effectiveness against a specific type of metastatic melanoma, which is a kind of skin cancer. They did not specify which type of melanoma will be studied.

If the combination works and is safe, the companies may continue development of the combination.

Yervoy is an injectable drug, and it is approved to treat melanoma that has metastasized and is inoperable. It is the first drug for advanced melanoma that is designed to increase survival.

Bristol-Myers is based in New York, and Roche is based in Basel, Switzerland.

Print
Email
|